165948-24-3

Basic information

• Product Name: TERT-BUTYL 6,7-DIHYDROTHIAZOLO[5,4-C]PYRIDINE-5(4H)-CARBOXYLATE
• Synonyms: TERT-BUTYL 6,7-DIHYDRO[1,3]THIAZOLO[5,4-C]PYRIDINE-5(4H)-CARBOXYLATE;TERT-BUTYL 6,7-DIHYDROTHIAZOLO[5,4-C]PYRIDINE-5(4H)-CARBOXYLATE;tert-Butyl 6,7-dihydrothiazolo[5,4-c]pyridin-5(4H)-carboxylate;tert-butyl 4H,5H,6H,7H-[1,3]thiazolo[5,4-c]pyridine-5-carboxylate;Thiazolo[5,4-c]pyridine-5(4H)-carboxylicacid, 6,7-dihydro-, 1,1-diMethylethyl ester;6,7-Dihydro-4H-thiazolo[5,4-c]pyridine-5-carboxylic acid tert-butyl ester
• CAS NO: 165948-24-3
• Molecular Formula: C11H16N2O2S
• Molecular Weight: 240.32
• Mol File: 165948-24-3.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 357.5±42.0 °C(Predicted)
• Appearance: /
• Density: 1.218±0.06 g/cm3(Predicted)
• PKA: 2.90±0.20(Predicted)
• CAS DataBase Reference: TERT-BUTYL 6,7-DIHYDROTHIAZOLO[5,4-C]PYRIDINE-5(4H)-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL 6,7-DIHYDROTHIAZOLO[5,4-C]PYRIDINE-5(4H)-CARBOXYLATE(165948-24-3)
• EPA Substance Registry System: TERT-BUTYL 6,7-DIHYDROTHIAZOLO[5,4-C]PYRIDINE-5(4H)-CARBOXYLATE(165948-24-3)

Safety Data

• Hazardous Substances Data: 165948-24-3(Hazardous Substances Data)

Usage

General Description

TERT-BUTYL 6,7-DIHYDROTHIAZOLO[5,4-C]PYRIDINE-5(4H)-CARBOXYLATE is a chemical compound with the molecular formula C14H20N2O2S. It is a heterocyclic compound that contains a thiazole ring and a pyridine ring. This chemical is commonly used in the pharmaceutical industry as a building block for the synthesis of various organic compounds, particularly for the development of new drugs and medicinal products. Its tert-butyl ester group enhances its stability and makes it a versatile intermediate for the production of a wide range of organic compounds. Its unique structure and properties make it a valuable component in the synthesis of pharmaceuticals and other biologically active molecules.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 165948-22-1 5-Ethoxycarbonyl-4,5,6,7-tetrahydrothiazolo[5,4-c]-pyridine 
• 89424-04-4 3-chloro-1-ethoxycarbonyl-4-piperidone 
• 165948-23-2 4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine 
• 365996-06-1 2-Bromo-5-tert-butoxycarbonyl-4,5,6,7-tetrahydro-thiazolo[5,4-c]pyridine 
• 365996-05-0 tert-butyl 2-amino-6,7-dihydrothiazolo[5,4-c]pyridine-5(4H)-carboxylate 
• 188869-05-8 tert-butyl 3-bromo-4-oxo-piperidine-1-carboxylate 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 

Downstream Products

• 165948-21-0 5-(tert-butoxycarbonyl)-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxylic acid 
• 165948-23-2 4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine 
• 758685-72-2 5-methyl-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridine-2-carboxylic acid 

Relevant articles and documents

Heterocyclic compound with Wnt signal path inhibitory activity and application thereof

The invention provides a heterocyclic compound with Wnt signal path inhibitory activity. The heterocyclic compound and chemically acceptable salt, isotope, isomer and a crystal structure thereof are provided with a structure shown as the general formula I (see the formula in the description). The invention further provides application of the heterocyclic compound with the Wnt signal path inhibitory activity. The heterocyclic compound with the Wnt signal path inhibitory activity serves as effective antagonist of a Wnt signal path, and can be used for treating or preventing diseases caused by abnormity of the Wnt signal path.

DIAMINE DERIVATIVES

A compound represented by formula (1):Q1-Q2-To-N(R1) -Q3-N(R2)-T1-Q4 [wherein R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6- membered cyclic hydrocarbon group which may be substituted, or the like; Q2 is a single bond or the like; Q3 represents the following group: (wherein Q5 is an alkylene group having 1 to 8 carbon atoms, or the like); and T0 and T1 are carbonyl groups or the like], a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after artificial valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

Orally active factor Xa inhibitors: 4,5,6,7-tetrahydrothiazolo[5,4-c] pyridine derivatives

In our investigation of factor Xa inhibitors, a series of 1-(6-chloronaphthalen-2-yl)sulfonyl-4-(4,5,6,7-tetrahydrothiazolo[5,4-c] pyridine-2-carbonyl)piperazines 3a-i were synthesized. In vitro inhibitory activities of the compounds against factor Xa and coagulation are summarized. Among the compounds, 3c and 3d, possessing a carbamoyl or N-methylcarbamoyl moiety, showed potent inhibitory activities when administered orally to rats.